The Promise of Seamless Clinical Trials

For decades, drug development has relied on the predictable, sequential cadence of Phase I, Phase II, and Phase III trials. This traditional paradigm, while rigorous, is slow, inefficient, and ill-suited for the rapid advancement of modalities like gene therapies and targeted oncology.

At Highlander Health, we believe the future of evidence generation incorporates continuous clinical trials, also known as “seamless trials.” Seamless trials should not be seen as just an efficiency hack, but rather a fundamental recalibration of how we maximize learning from every study participant.

The Core Idea: Adaptive Continuity

Instead of starting, stopping, collating, analyzing, discussing, and restarting three separate trials, a biopharma company designs a single, contingent protocol that integrates multiple development stages into a single, continuously adapting trial.

As FDA Commissioner Dr. Marty Makary has noted, the sequential model is like "applying for college after every year of college." The model inherently builds in unnecessary downtime, start-up costs, and regulatory gaps.

Seamless trials eliminate these administrative pauses by leveraging pre-specified interim analyses. Once a certain amount of data accrues, the trial automatically adapts based on predefined rules. This can manifest in dropping less promising treatment arms, adjusting dose levels, or expanding promising patient cohorts. This seamless approach is especially well-suited for rare cancers and small patient populations, where maximizing data learning from every enrolled patient is non-negotiable (as highlighted in a recent white paper by Friends of Cancer Research).

Two Choices for a Seamless Approach: Operational vs. Inferential

While the core concept is the same, seamless trials generally fall into two statistical and operational buckets:

1. Operationally Seamless Designs

In this approach, the primary goal of the protocol is speed and minimal disruptions in transition. The data collected from the early stage and the later stage of the continuous trial are analyzed separately. Researchers place a strong focus on operational efficiency. For example, rapidly transitioning from a dose-finding stage (traditional Phase I) to an efficacy expansion stage (traditional Phase II/III) without the lengthy pause for writing a new protocol and filing a separate IND amendment. The benefit of an operationally seamless design is reduced administrative downtime and expedited site activation.

2. Inferentially Seamless Designs

Inferentially seamless trial design refers to a deeper, more integrated approach. Under this design, subjects carry their treatment arm from before and after the interim analysis, and the data from both "phases" are statistically pooled and analyzed together to support the final efficacy claim. The focus of this approach is to maximize both statistical power and data utility. This approach contains many benefits, most notably that the smaller initial cohort contributes directly to the final registrational dataset, increasing the overall sample size and statistical power.

Embracing a New Regulatory Climate

The shift toward seamless designs aligns perfectly with FDA's increasing focus on efficiency. Programs like the Oncology Center of Excellence's Project Optimus encourage randomized dose optimization within earlier, adaptive trials. Furthermore, the goals of the new Commissioner’s National Priority Voucher Program (CNPVP), which seeks to radically reduce review times, are predicated on the idea that the FDA has a better, real-time awareness of the data as it’s generated.

Reflecting back on the shifting paradigm of evidence generation to continuous evaluation of medical products across their life cycle, as detailed in our blog on Highlander Health’s Snail, seamless trials are an engine that turbocharges this shift. The goal is to generate high-quality evidence faster, more efficiently, and with greater statistical rigor.